Protox to present at BioFinance 2007



    VANCOUVER, April 24 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX)
announced today that Dr. Fahar Merchant, President and CEO of Protox, will
present a corporate update at BioFinance to be held at the Marriot Eaton
Centre Hotel in Toronto, Ontario on Wednesday, April 25, 2007 at 3:30 p.m. EDT
in Trinity Room II.

    About Protox

    Protox Therapeutics is a leader in advancing novel, targeted therapeutics
for treatment of cancer and other proliferative diseases. The company is
actively developing two distinct but complementary platforms, INxin(TM) and
PORxin(TM), and currently has four clinical programs in development. A Phase
IIa clinical trial into the use of PRX321 (INxin) for the treatment of primary
brain cancer has been completed and the drug has received Fast Track
Designation and Orphan Drug Status from the US FDA. In addition, a Phase I
trial has been completed for PRX321 to treat patients with renal cell
carcinoma and non-small cell lung cancer. Patient enrolment is underway for
two Phase I clinical trials using PRX302 (PORxin) for prostatic disease: one
to treat localized prostate cancer and the other to treat benign prostatic
hyperplasia.

    NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS
    RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE
    ADEQUACY OR ACCURACY OF THIS RELEASE.

    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.





For further information:

For further information: James Beesley, Director, Investor Relations,
Protox Therapeutics, (604) 688-0199, jbeesley@protoxtherapeutics.com; Michael
Moore, Investor Relations, Equicom Group, (416) 815-0700 x241,
mmoore@equicomgroup.com

Organization Profile

Sophiris Bio, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890